Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2018 07:30 ET | Source: InspireMD, Inc.

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
August 06, 2018 16:05 ET | Source: InspireMD, Inc.

InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
July 23, 2018 08:41 ET | Source: InspireMD, Inc.

InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence

Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
June 29, 2018 10:24 ET | Source: InspireMD, Inc.

InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

Tel Aviv, Israel, June 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
June 20, 2018 07:20 ET | Source: InspireMD, Inc.

InspireMD’s CGuard EPS Featured at the SBHCI Congress in Brazil

Tel Aviv, Israel, June 20, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
June 11, 2018 09:53 ET | Source: InspireMD, Inc.

InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress

Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
May 30, 2018 07:31 ET | Source: InspireMD, Inc.

InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS

Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE...
May 16, 2018 08:12 ET | Source: InspireMD, Inc.

InspireMD Receives Regulatory Approval for both CGuard EPS™ and MGuard Prime™ in Ecuador

Tel Aviv, Israel, May 16, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
May 07, 2018 16:05 ET | Source: InspireMD, Inc.

InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018

Tel Aviv, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
May 01, 2018 07:00 ET | Source: InspireMD, Inc.

InspireMD Schedules First Quarter 2018 Earnings Conference Call

TEL AVIV, ISRAEL , May 01, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...

Next Page keyboard_arrow_right